Sandoz has filed a petition for inter partes review of AbbVie’s U.S. Patent No. 8,802,100 (IPR2017-01823), which claims stable formulations of an anti-TNFα antibody identified in the petition as Humira® (adalimumab). Sandoz also filed a petition for inter partes review of AbbVie’s U.S. Patent No. 9,512,216 (IPR2017-01824), which claims a dosing regimen of an antibody identified in the petition as Humira® to treat chronic plaque psoriasis.
These petitions and other selected PTAB filings concerning biologics are posted on our IPR Tracker Page.
The post Sandoz Files Two Petitions for IPR of Two AbbVie Patents Related to Humira appeared first on Big Molecule Watch.